Financière de Tubize SA (TUB.BR)
EUR 138.8
(-0.86%)
EUR 138.8
(-0.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 78.62 Million EUR | 68.25% |
| 2022 | 46.73 Million EUR | 1028.5% |
| 2021 | 4.14 Million EUR | -87.27% |
| 2020 | 32.53 Million EUR | -62.19% |
| 2019 | 86.03 Million EUR | -39.02% |
| 2018 | 141.08 Million EUR | -26.01% |
| 2017 | 190.69 Million EUR | -20.66% |
| 2016 | 240.33 Million EUR | -15.59% |
| 2015 | 284.72 Million EUR | 54.74% |
| 2014 | 184 Million EUR | -17.01% |
| 2013 | 221.71 Million EUR | -13.12% |
| 2012 | 255.2 Million EUR | -10.71% |
| 2011 | 285.81 Million EUR | -8.99% |
| 2010 | 314.03 Million EUR | -7.55% |
| 2009 | 339.69 Million EUR | -3.15% |
| 2008 | 350.74 Million EUR | 4054.67% |
| 2007 | -8.86 Million EUR | -104.15% |
| 2006 | 213.78 Million EUR | 122.25% |
| 2005 | 96.19 Million EUR | -10.76% |
| 2004 | 107.78 Million EUR | -12.73% |
| 2003 | 123.51 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 30.49 Million EUR | 0.0% |
| 2023 FY | 78.62 Million EUR | 68.25% |
| 2023 Q2 | 46.31 Million EUR | 0.0% |
| 2023 Q4 | 78.62 Million EUR | 0.0% |
| 2022 Q2 | 44.72 Million EUR | 0.0% |
| 2022 FY | 46.73 Million EUR | 1028.5% |
| 2022 Q4 | 46.73 Million EUR | 0.0% |
| 2021 FY | 4.14 Million EUR | -87.27% |
| 2021 Q4 | 4.14 Million EUR | 0.0% |
| 2021 Q2 | -2.26 Million EUR | 0.0% |
| 2020 FY | 32.53 Million EUR | -62.19% |
| 2020 Q4 | 32.53 Million EUR | 0.0% |
| 2020 Q2 | 30.29 Million EUR | 0.0% |
| 2019 Q2 | 84.97 Million EUR | 0.0% |
| 2019 Q4 | 86.03 Million EUR | 0.0% |
| 2019 FY | 86.03 Million EUR | -39.02% |
| 2018 Q4 | 141.08 Million EUR | 0.0% |
| 2018 FY | 141.08 Million EUR | -26.01% |
| 2018 Q2 | 137.82 Million EUR | 0.0% |
| 2017 Q2 | 189.11 Million EUR | 0.0% |
| 2017 FY | 190.69 Million EUR | -20.66% |
| 2017 Q4 | 190.69 Million EUR | 0.0% |
| 2016 FY | 240.33 Million EUR | -15.59% |
| 2016 Q2 | 237.57 Million EUR | 0.0% |
| 2016 Q4 | 240.33 Million EUR | 0.0% |
| 2015 FY | 284.72 Million EUR | 54.74% |
| 2015 Q2 | 143.78 Million EUR | 0.0% |
| 2015 Q4 | 284.72 Million EUR | 0.0% |
| 2014 Q4 | 184 Million EUR | 0.0% |
| 2014 Q2 | 178.86 Million EUR | 0.0% |
| 2014 FY | 184 Million EUR | -17.01% |
| 2013 FY | 221.71 Million EUR | -13.12% |
| 2013 Q4 | 221.71 Million EUR | 0.0% |
| 2013 Q2 | 209.36 Million EUR | 0.0% |
| 2012 Q4 | 255.2 Million EUR | 0.0% |
| 2012 Q2 | 296.84 Million EUR | 0.0% |
| 2012 FY | 255.2 Million EUR | -10.71% |
| 2011 Q2 | 273.69 Million EUR | 0.0% |
| 2011 FY | 285.81 Million EUR | -8.99% |
| 2011 Q4 | 285.81 Million EUR | 0.0% |
| 2010 Q2 | 301.88 Million EUR | 0.0% |
| 2010 FY | 314.03 Million EUR | -7.55% |
| 2010 Q4 | 314.03 Million EUR | 0.0% |
| 2009 Q4 | 339.69 Million EUR | 0.0% |
| 2009 FY | 339.69 Million EUR | -3.15% |
| 2008 FY | 350.74 Million EUR | 4054.67% |
| 2007 FY | -8.86 Million EUR | -104.15% |
| 2006 FY | 213.78 Million EUR | 122.25% |
| 2005 FY | 96.19 Million EUR | -10.76% |
| 2004 FY | 107.78 Million EUR | -12.73% |
| 2003 FY | 123.51 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 11111.927% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 140.017% |
| Adocia SA | 127 Thousand EUR | -61809.574% |
| Aelis Farma SA | -16.19 Million EUR | 585.58% |
| Biophytis S.A. | 2.7 Million EUR | -2808.811% |
| Advicenne S.A. | 12.17 Million EUR | -545.792% |
| genOway Société anonyme | 2.97 Million EUR | -2544.668% |
| IntegraGen SA | -709.74 Thousand EUR | 11177.882% |
| Medesis Pharma S.A. | 1.15 Million EUR | -6688.506% |
| Neovacs S.A. | -237.08 Thousand EUR | 33262.999% |
| NFL Biosciences SA | -2.27 Million EUR | 3554.73% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1704.774% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 9566.66% |
| Sensorion SA | 1.37 Million EUR | -5604.825% |
| Theranexus Société Anonyme | 2.44 Million EUR | -3116.865% |
| TME Pharma N.V. | -1.07 Million EUR | 7386.854% |
| Valbiotis SA | -18.13 Million EUR | 533.459% |
| TheraVet SA | 12.78 Thousand EUR | -614879.734% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -3506.659% |
| argenx SE | -1.83 Billion EUR | 104.281% |
| BioSenic S.A. | 28.04 Million EUR | -180.364% |
| Celyad Oncology SA | -6.1 Million EUR | 1388.515% |
| DBV Technologies S.A. | -114.95 Million USD | 168.396% |
| Galapagos NV | -157.2 Million EUR | 150.014% |
| Genfit S.A. | -7.61 Million EUR | 1133.046% |
| GeNeuro SA | 5.91 Million EUR | -1230.285% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 413.098% |
| Innate Pharma S.A. | -30.71 Million EUR | 356.008% |
| Inventiva S.A. | 10.48 Million EUR | -649.596% |
| MaaT Pharma SA | -10.2 Million EUR | 870.457% |
| MedinCell S.A. | 39.5 Million EUR | -99.046% |
| Nanobiotix S.A. | -24.71 Million EUR | 418.089% |
| Onward Medical N.V. | -12.89 Million EUR | 709.781% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -5396.979% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | -189.82% |
| Oxurion NV | 10.71 Million EUR | -634.128% |
| Pharming Group N.V. | 99.4 Million EUR | 20.902% |
| Poxel S.A. | 44.55 Million EUR | -76.452% |
| GenSight Biologics S.A. | 16.29 Million EUR | -382.541% |
| Transgene SA | -14.4 Million EUR | 645.667% |
| UCB SA | 2.17 Billion EUR | 96.388% |
| Valneva SE | 82.73 Million EUR | 4.969% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 524.45% |